Abstract：
UNASSIGNED: Bladder cancer (BC) has a particular importance in Egyptian patients due to aggressive behavior and absence of prognostic markers.
UNASSIGNED: To evaluate the expression of gene and protein expression of HER2 and epidermal growth factor (EGFR) in Egyptian patients with BC and ultimately to investigate their clinical implication and prognostic significance.
UNASSIGNED: The study was carried out on 46 patients with urothelial bladder BC. Tissue were obtained from transurethral resection (N = 22) and radical cystectomy (N = 24) specimens. The original hematoxylin and eosin slides were re-evaluated and the formalin fixed, paraffin-embedded (FFPE) tissues which had sufficient tumor tissue (>75%) and minimal or absent tumor necrosis were selected for immunohistochemistry (IHC) and RNA extraction. Furthermore, five control biopsies were obtained from patients with cystitis. Follow-up data were retrieved from the medical records which included the treatment regimen, disease recurrence and/or progression, and survival.
UNASSIGNED: EGFR and HER2 protein were overexpressed in 35% and 46% of patients respectively. EGFR was correlated with the tumor size, grade and pathological stage, with a similar trend for HER2. The recurrence rate was higher in patients with expression of any of the markers. Gene expression was significantly higher (10.6-folds) for EGFR and (21-folds) for HER2 in patients with BC in comparison to control patients. Survival analysis showed lower median disease-free survival in association with HER2 protein overexpression.
UNASSIGNED: Our data highlighted the prognostic significance of EGFR and HER in BC and proposed their possible use as predictive markers and potential therapeutic targets.
UNASSIGNED: To evaluate the expression of gene and protein expression of HER2 and epidermal growth factor (EGFR) in Egyptian patients with BC and ultimately to investigate their clinical implication and prognostic significance.
UNASSIGNED: The study was carried out on 46 patients with urothelial bladder BC. Tissue were obtained from transurethral resection (N = 22) and radical cystectomy (N = 24) specimens. The original hematoxylin and eosin slides were re-evaluated and the formalin fixed, paraffin-embedded (FFPE) tissues which had sufficient tumor tissue (>75%) and minimal or absent tumor necrosis were selected for immunohistochemistry (IHC) and RNA extraction. Furthermore, five control biopsies were obtained from patients with cystitis. Follow-up data were retrieved from the medical records which included the treatment regimen, disease recurrence and/or progression, and survival.
UNASSIGNED: EGFR and HER2 protein were overexpressed in 35% and 46% of patients respectively. EGFR was correlated with the tumor size, grade and pathological stage, with a similar trend for HER2. The recurrence rate was higher in patients with expression of any of the markers. Gene expression was significantly higher (10.6-folds) for EGFR and (21-folds) for HER2 in patients with BC in comparison to control patients. Survival analysis showed lower median disease-free survival in association with HER2 protein overexpression.
UNASSIGNED: Our data highlighted the prognostic significance of EGFR and HER in BC and proposed their possible use as predictive markers and potential therapeutic targets.
摘要：
未经证实：膀胱癌（BC）在埃及患者中由于攻击行为和缺乏预后标志物而特别重要。
UNASSIGNED：评估埃及BC患者HER2和表皮生长因子（EGFR）的基因和蛋白表达，并最终探讨其临床意义和预后意义。
UNASSIGNED：该研究对46例尿路上皮性膀胱BC患者进行。组织从经尿道切除术（N=22）和根治性膀胱切除术（N=24）标本中获得。重新评估原始苏木精和伊红载玻片，并固定福尔马林，选择具有足够肿瘤组织(>75%)和最小或不存在肿瘤坏死的石蜡包埋(FFPE)组织用于免疫组织化学(IHC)和RNA提取。此外，5例对照活检来自膀胱炎患者.从包括治疗方案在内的医疗记录中检索随访数据，疾病复发和/或进展，和生存。
未经证实：EGFR和HER2蛋白分别在35%和46%的患者中过表达。EGFR与肿瘤大小相关,分级和病理分期，与HER2的趋势相似。任何标志物表达的患者复发率较高。与对照患者相比，BC患者的EGFR基因表达明显更高（10.6倍），HER2基因表达明显更高（21倍）。生存分析显示与HER2蛋白过表达相关的中位无病生存率较低。
UASSIGNED：我们的数据强调了EGFR和HER在BC中的预后意义，并提出了它们作为预测标志物和潜在治疗靶点的可能用途。
UNASSIGNED：评估埃及BC患者HER2和表皮生长因子（EGFR）的基因和蛋白表达，并最终探讨其临床意义和预后意义。
UNASSIGNED：该研究对46例尿路上皮性膀胱BC患者进行。组织从经尿道切除术（N=22）和根治性膀胱切除术（N=24）标本中获得。重新评估原始苏木精和伊红载玻片，并固定福尔马林，选择具有足够肿瘤组织(>75%)和最小或不存在肿瘤坏死的石蜡包埋(FFPE)组织用于免疫组织化学(IHC)和RNA提取。此外，5例对照活检来自膀胱炎患者.从包括治疗方案在内的医疗记录中检索随访数据，疾病复发和/或进展，和生存。
未经证实：EGFR和HER2蛋白分别在35%和46%的患者中过表达。EGFR与肿瘤大小相关,分级和病理分期，与HER2的趋势相似。任何标志物表达的患者复发率较高。与对照患者相比，BC患者的EGFR基因表达明显更高（10.6倍），HER2基因表达明显更高（21倍）。生存分析显示与HER2蛋白过表达相关的中位无病生存率较低。
UASSIGNED：我们的数据强调了EGFR和HER在BC中的预后意义，并提出了它们作为预测标志物和潜在治疗靶点的可能用途。
